• Login
    View Item 
    •   DSpace Home
    • ADU Repository
    • Business
    • Accounting & Finance
    • View Item
    •   DSpace Home
    • ADU Repository
    • Business
    • Accounting & Finance
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Valuation Implications of Pharmaceutical Companies’ R&D Regulatory Approval Notifications

    Thumbnail
    View/Open
    Valuation Implications of Pharmaceutical Companies’ R&D Regulatory Approval Notifications (167.1Kb)
    Date
    2013
    Author
    Hamill, Philip
    K, Opong
    P, McIlkenny
    Metadata
    Show full item record
    Abstract
    This paper examines shareholder wealth effects surrounding applications to, and approvals by, the United States Food and Drug Administration (FDA) for firms listed on the New York (NYSE) and London (LSE) stock exchanges. Applications to the FDA for drug approvals significantly increase shareholder wealth for NYSE firms only. The increase is driven by applications for enhancements to existing drugs, with the market anticipating the application, thus suggesting information leakage. FDA approvals also significantly increase shareholder wealth in both markets. However, there is no evidence of information leakage and the significant post-event abnormal returns support the attention-grabbing hypothesis. Enhanced drug approvals are value-relevant for both markets, which highlights the contribution of real-options to firm value.
    URI
    https://dspace.adu.ac.ae/handle/1/1519
    DOI
    https://doi.org/10.1016/j.bar.2013.03.004
    Collections
    • Accounting & Finance

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    Atmire NV
     

     

    Browse

    All of DSpaceCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    DSpace software copyright © 2002-2016  DuraSpace
    Contact Us | Send Feedback
    Theme by 
    Atmire NV